Patents by Inventor Liang Deng

Liang Deng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250136702
    Abstract: Provided are a human LIFR antigen binding protein, a preparation method therefor, and an application thereof. A series of human LIFR antibodies having biological functions are obtained using human LIFR-ECD protein immune H2L2 humanized antibody transgenic mice by means of single B cell cloning technology (SBC), single B cell sequencing analysis, and Fc recombination. The method greatly improves the discovery efficiency and the yield of antibody drugs, and the obtained human LIFR antibody has good affinity and can block the binding of huLIF proteins to huLIFR/gp130 cells, thereby inhibiting signaling pathways such as STAT3, further inhibiting the growth of tumors, and achieving the purpose of tumor prevention and treatment.
    Type: Application
    Filed: December 29, 2021
    Publication date: May 1, 2025
    Applicants: NONA BIOSCIENCES (SUZHOU) CO., LTD., YINUOKE BIOMEDICAL CO., LTD.
    Inventors: Yanni CONG, Lingbing ZHANG, Changjing DENG, Guangbei ZHU, Liang ZHOU, Ruipeng MA, Yin CHEN, Lile LIU
  • Publication number: 20250129135
    Abstract: The present application relates to the pharmaceutical and biological fields, particularly relates to a polypeptide compound of general formula (I) with triple agonist activity on glucagon like peptide-1 receptor (GLP-1 R), glucose-dependent insulinotropic polypeptide receptor (GIP R), and glucagon receptor (GCG R), and use thereof in the treatment of metabolic syndrome.
    Type: Application
    Filed: May 18, 2022
    Publication date: April 24, 2025
    Applicant: The United Bio-Technology (Hengqin) Co., Ltd
    Inventors: Liang HUANG, Chunlai CAO, Huixing DENG, Cui ZHOU, Xiuyi HE, Xiaoxiao LIU, Xin XIE
  • Patent number: 12269403
    Abstract: The main driver information acquisition-based vehicle control system comprises a first ECU, a vehicle-mounted storage battery, a second ECU separately connected to the first ECU and the vehicle-mounted storage battery, and a microphone connected to the second ECU. The microphone is embedded on a door handle on one side of the driving position, and is used for obtaining voiceprint information. The second ECU is used for comparing the voiceprint information with a pre-entered voiceprint sample of a main driver, determining whether the voiceprint information is the main driver's, monitoring the electronic start status of a vehicle when the voiceprint information is the main driver's, and notifying the first ECU to control, according to preference information of the main driver, a device corresponding to the preference information of the main driver when monitoring that the vehicle enters an ACC or one-button start mode.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: April 8, 2025
    Assignee: GUANGZHOU AUTOMOBILE GROUP CO., LTD.
    Inventors: Min Wang, Guizhong Deng, Guangwei Ran, Weiliang Luo, Liang Li, Pengxiang Chen
  • Publication number: 20250113087
    Abstract: The present disclosure describes techniques for implementing video segmentation. A video is divided into a plurality of clips. Each of the plurality of clips comprises several frames. Axial-trajectory attention is applied to each of the plurality of clips by a first sub-model. Clip features corresponding to each of the plurality of clips are generated by the first sub-model. A set of object queries corresponding to each of the plurality of clips is generated based on the clip features by a transformer decoder. Trajectory attention is applied to refine sets of object queries corresponding to the plurality of clips by a second sub-model. Video-level segmentation results are generated based on the refined object queries.
    Type: Application
    Filed: December 22, 2023
    Publication date: April 3, 2025
    Inventors: Ju He, Qihang Yu, Inkyu Shin, Xueqing Deng, Xiaohui Shen, Liang-Chieh Chen
  • Patent number: 12258419
    Abstract: The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: March 25, 2025
    Assignees: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Klus Pharma Inc.
    Inventors: Haijun Tian, Dengnian Liu, Sujun Deng, Marc Peter Ciucci, Cheng Wang, Yong Zheng, Liang Xiao, Tongtong Xue, Jingyi Wang
  • Patent number: 12252702
    Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: March 18, 2025
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Liang Deng, Jedd Wolchok, Stewart Shuman, Taha Merghoub, Ning Yang, Yi Wang, Gregory Mazo, Peihong Dai, Weiyi Wang
  • Patent number: 12234040
    Abstract: A multi-purpose planet planetary exploration rover is provided in this invention, which relates to the field of planet exploration. The multi-purpose planetary exploration rover includes a case body, mounted with a first wheel at left and right sides respectively; and a cantilever, having a front end connected to the case body, a rear end of the cantilever being mounted with a second wheel; wherein the cantilever is rotated or fixed relative to the case body, the second wheel is steered relative to the cantilever, and the first wheel and the second wheel are used to drive the multi-purpose planetary exploration rover. Compared with the prior art, the multi-purpose planetary exploration rover of this invention can effectively explore special geographic locations such as cliffs, volcanic craters, craters and lava caves on alien planets.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: February 25, 2025
    Assignee: Harbin Institute of Technology
    Inventors: Haibo Gao, Huaiguang Yang, Lan Huang, Liang Ding, Zhaowei Yu, Zongquan Deng, Haitao Yu
  • Publication number: 20250045929
    Abstract: Single-stage frameworks for open-vocabulary panoptic segmentation are provided.
    Type: Application
    Filed: August 3, 2023
    Publication date: February 6, 2025
    Inventors: Qihang Yu, Ju He, Xueqing Deng, Xiaohui Shen, Liang-Chieh Chen
  • Patent number: 12214045
    Abstract: Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.
    Type: Grant
    Filed: July 12, 2023
    Date of Patent: February 4, 2025
    Assignee: Nektar Therapeutics
    Inventors: Zhongxu Ren, Neel K. Anand, Haiying Cai, Bo-Liang Deng, Bhalchandra V. Joshi, Jonathan Zalevsky, Takahiro Miyazaki, Saul Kivimae
  • Publication number: 20250004819
    Abstract: The disclosure relates to a data processing method, apparatus, readable medium, computing device, computer program product, and computer program. The method is implemented at a computing device. A virtual machine is executed in the computing device. The method includes: in response to a target virtual device receiving a data read/write request, writing, into a shared memory, target data comprised in the data read/write request, the target virtual device being a virtual device in the virtual machine; sending an interrupt instruction to a target physical processor in the computing device through a pass-through register corresponding to the target virtual device, the interrupt instruction being used by the target physical processor to acquire the target data from the shared memory according to the interrupt instruction, and inform, based on the target data, a corresponding back-end service program to process the data read/write request.
    Type: Application
    Filed: September 16, 2024
    Publication date: January 2, 2025
    Inventors: Hangjing LI, Liang DENG, Yongji XIE, Wen CHAI, Jian WANG
  • Publication number: 20240429247
    Abstract: An array substrate and a method for manufacturing an array substrate. The array substrate includes a display region and a non-display region. The non-display region is located at least on one side of the display region. The array substrate also includes a substrate, a driver circuit layer, and a pad layer. The substrate includes a first surface and a second surface that are disposed opposite to each other and a side surface connected to the first surface and the second surface. The driver circuit layer is disposed on the first surface and includes at least one signal layer. The at least one signal layer extends from the display region to the non-display region. The pad layer is disposed in the display region and includes at least one pad. The at least one pad is electrically connected to the at least one signal layer.
    Type: Application
    Filed: June 24, 2024
    Publication date: December 26, 2024
    Applicant: Chengdu Vistar Optoelectronics Co., Ltd.
    Inventors: Zhen ZHANG, Xiuqi HUANG, Xuan CAO, Zongyi XIONG, Fei HUANG, Yunlei CHEN, Aimin XING, Liang DENG, Zhibo YAO
  • Publication number: 20240378075
    Abstract: The disclosure relates to a method, non-transitory computer-readable storage medium, and device of virtual machine resource allocation. The method includes: when virtual machines are created in a physical machine, allocating corresponding bare machine devices to the virtual machine, the bare machine devices being obtained by segmenting physical resources of the physical machine, and the virtual machine being in one-to-one correspondence with the bare machine devices; configuring the operation mode of the bare machine devices into a non-root mode; and switching the operation mode of a CPU of the physical machine to the non-root mode so as to start the virtual machines in the bare machine devices.
    Type: Application
    Filed: October 11, 2022
    Publication date: November 14, 2024
    Inventors: Liang DENG, Yongji XIE, Hangjing LU, Xiongchun DUAN, Wen CHAI, Yu ZHANG, Jian WANG
  • Patent number: 12054553
    Abstract: Provided is a method of administering to a patient having cancer: (a) a 4-1BB agonist; (b) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and/or (c) a toll-like receptor agonist, as well as related compositions, kits and compositions.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: August 6, 2024
    Assignee: Nektar Therapeutics
    Inventors: Saul Kivimae, Marlene Hennessy, Neel K. Anand, Haiying Cai, Bo-Liang Deng, Zhongxu Ren, Bhalchandra V. Joshi
  • Patent number: 12036279
    Abstract: The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVA?E3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: July 16, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Jedd Wolchok, Taha Merghoub, Weiyi Wang, Peihong Dai, Ning Yang
  • Patent number: 12030940
    Abstract: Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2R?-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: July 9, 2024
    Assignee: Nektar Therapeutics
    Inventors: Jonathan Zalevsky, Neel K. Anand, Haiying Cai, Bo-Liang Deng, Zhongxu Ren, Bhalchandra V. Joshi, Mary Tagliaferri, Werner Rubas, Saul Kivimae, Rhoneil L. Pena
  • Patent number: 11986503
    Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK?) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: May 21, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Jedd Wolchok, Taha Merghoub, Weiyi Wang, Peihong Dai, Ning Yang
  • Publication number: 20240119991
    Abstract: In an embodiment, a memory controller in an integrated circuit may generate refreshes for one or more DRAMs coupled to the integrated circuit according to a refresh rate. The integrated circuit may include one or more temperature sensors. A rate of change of the temperature may be determined from the temperature sensors. If the rate is greater than a threshold, the memory controller may generate refreshes according to a refresh rate specified by the DRAMs. If the rate is less than the threshold, the memory controller may generate refreshes at a reduced refresh rate.
    Type: Application
    Filed: October 17, 2023
    Publication date: April 11, 2024
    Inventors: Liang Deng, Norman J. Rohrer, Yizhang Yang, Arpit Mittal
  • Patent number: 11949282
    Abstract: Disclosed are an offline uninterruptible power source and a control method therefor.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: April 2, 2024
    Assignee: Lian Zheng Electronics (Shenzhen) Co., Ltd.
    Inventors: Wuhua Hu, Liang Deng
  • Patent number: 11884939
    Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVA?C7L and VACV?C7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVA?C7L or VACV?C7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: January 30, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Ning Yang, Taha Merghoub, Jedd Wolchok
  • Patent number: 11842700
    Abstract: Throttling circuitry may throttle the backlight reconstruction via backlight reconstruction and compensation circuitry in a display pipeline when power may be limited. This throttling of the display pipeline may limit a number of cycles that may be used for performing backlight reconstruction and compensation.
    Type: Grant
    Filed: February 14, 2023
    Date of Patent: December 12, 2023
    Assignee: Apple Inc.
    Inventors: Prabhu Rajamani, Liang Deng, Oren Kerem, Meir Harar, Ido Yaacov Soffair, Assaf Menachem, John H. Kelm, Rohit K. Gupta